Tesaro - Moonstone for Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and effective the study drugs (Niraparib and TSR-042) are to treat platinum-resistant ovarian cancer.
What is the Condition Being Studied?
Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who Can Participate in the Study?

Adults who:
- Have relapsed ovarian, Fallopian tube, or primary peritoneal cancer
- Have had no more than 3 prior treatments for your cancer

Age Group

What is Involved?

If you choose to join this study you will:
- Take the study drug (Niraparib) for 3 weeks
- Get an infusion (into your vein) of the study drug (TSR-042) once a week for 3 months
- Get a physical every 3 weeks

Study Details

Full Title
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (Moonstone)
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB: PRO00102918
NCT: NCT03955471
Phase II
Contact the Duke Recruitment Innovation Center